Join Growin Stock Community!

Cassava sciences, inc.SAVA.US Overview

US StockHealthcare
(No presentation for SAVA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SAVA AI Insights

SAVA Overall Performance

SAVA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SAVA Recent Performance

-5.10%

Cassava sciences, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

SAVA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SAVA Key Information

SAVA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SAVA Profile

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Price of SAVA

SAVA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SAVA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.19
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.39
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.19
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.39
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is SAVA's latest earnings report released?

    The most recent financial report for Cassava sciences, inc. (SAVA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SAVA's short-term business performance and financial health. For the latest updates on SAVA's earnings releases, visit this page regularly.

  • How much cash does SAVA have?

    At the end of the period, Cassava sciences, inc. (SAVA) held Total Cash and Cash Equivalents of 106.08M, accounting for 0.82 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does SAVA go with three margins increasing?

    In the latest report, Cassava sciences, inc. (SAVA) did not achieve the “three margins increasing” benchmark, with a gross margin of 50%%, operating margin of 8,330.71%%, and net margin of -1,286.55%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess SAVA's profit trajectory and future growth potential.

  • Is SAVA's EPS continuing to grow?

    According to the past four quarterly reports, Cassava sciences, inc. (SAVA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.22. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SAVA?

    Cassava sciences, inc. (SAVA)'s Free Cash Flow (FCF) for the period is -6.3M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 65.59% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SAVA?

    The latest valuation data shows Cassava sciences, inc. (SAVA) has a Price-To-Earnings (PE) ratio of -1.49 and a Price/Earnings-To-Growth (PEG) ratio of 0.04. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.